This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Flortaucipir F 18

Eli Lilly & Company

Drug Names(s): [F-18]T807, 18F-AV-1451, [18F]AV1451, [18F] AV-1451, AV-1451, Flortaucipir F18

Description: AV-1451 or [F-18]T807 is a novel tau PET imaging agent, reported to have a high affinity and selectivity to PHF-tau in the brain of Alzheimer's disease patients.

Deal Structure: In April 2013, Eli Lilly announced it has acquired two investigational positron emission tomography (PET) tracers from Siemens Medical Solutions USA. The tracers are intended to image tau (or neurofibrillary) tangles in the brain.

Lilly will initially focus on incorporating this new technology into its anti-amyloid and anti-tau research and development (R&D) programs. Lilly also has the option to commercialize the tracers. The tracers will be developed and validated by a team at Avid Radiopharmaceuticals, Lilly's wholly owned subsidiary focused on molecular imaging. Financial terms of the deal are not being disclosed.

Partners: Siemens AG

Flortaucipir F 18 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug